Bavarian Nordic Appoints James B. Breitmeyer as Executive Vice President and Divison President of its Cancer Vaccine Division
KVISTGAARD, Denmark - February 8, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that it has appointed James B. Breitmeyer, M.D., Ph.D. to the position of Executive Vice President and Division President of its Cancer Vaccine division.
"We are pleased to welcome Dr. Breitmeyer to our executive management team," commented Anders Hedegaard, President and CEO of Bavarian Nordic. "We believe that his long executive career in the pharmaceutical industry combined with his solid oncology expertise will provide the perfect leadership for our cancer vaccine division. He will apply more than two decades of clinical development experience from research through commercialization to the advancement of our cancer immunotherapy candidates, in particular PROSTVAC®, which is currently in Phase 3 development."
"I am very enthusiastic about joining Bavarian Nordic at this exciting time," said James B. Breitmeyer, M.D., Ph.D. "Immunotherapy of cancer is a career-long interest of mine, and I believe PROSTVAC® represents a state-of-the art approach, and a potentially improved treatment for patients suffering from advanced prostate cancer. I am looking forward to leading the development of this promising product candidate successfully through Phase 3 on its path towards commercialization."
Dr. Breitmeyer served as Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc. from 2006 to 2012. From 2001 to 2006, he served as Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. From 2000 to 2001, Dr. Breitmeyer served as President and Chief Executive Officer of the Harvard Clinical Research Institute. From 1991 to 2000, he held a variety of positions at Serono Laboratories Inc., including Chief Medical Officer and Senior Vice President of Research and Development. Prior to Serono, he served as a scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School.
Dr. Breitmeyer received his M.D. and Ph.D. from Washington University School of Medicine, is board certified in Internal Medicine and Oncology and is the author or co-author of numerous publications.
Chairman of the Board
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company’s lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company’s lead program is IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit www.bavarian-nordic.com
This announcement includes “forward-looking statements” that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Company Announcement no. 3 / 2013